AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$CDXS

Erbez Georgia sold $9K of CDXS

Erbez Georgia (See Remarks) sold 6,335 shares of CODEXIS, INC. (CDXS) at $1.36 on 2026-10-12.

Original reporting
SEC EDGAR · Erbez Georgia
Published Oct 14, 2026, 9:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CDXS
Neutral
high confidence
Mentioned
$CDXS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDXSNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock materially, but it provides transparency for investors monitoring insider activity.

02

Market read

Routine insider sale with minimal market impact; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: after-hours filing on 2026-10-14

Background

SEC Form 4 filing discloses an insider transaction by an officer of Codexis, a biotech company.

Company-level read

Ticker impact

$CDXSNeutralHigh confidence
Context

Officer Erbez Georgia sold 6,335 shares of Codexis for $8,619.40 on 2026-10-12, reducing her holding to 60,475 shares.

Expected impact

likely slight downward pressure as the market prices the insider sale

Evidence & confidence

The transaction amount is under $10k and represents a small fraction of total shares, so any price effect will be minimal.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Given the tiny size, the sale may be routine and not indicative of insider concern.

Key entities

  • company
    Codexis, Inc.

    Biotechnology firm listed on NASDAQ under ticker CDXS.

  • person
    Erbez Georgia

    Officer of Codexis who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CDXS insider trading history →

Related articles

AUG 19
$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

fool.com6 min
AUG 11
$CDXSMed

Codexis Reports Second Quarter 2026 Financial Results

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

SEC EDGAR 8-K6 min
JUL 23
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

SEC EDGAR 8-K2 min